Submission of newspaper publication of financial results for the fourth quarter and year ended March 31, 2025
Awaiting price reaction for this filing.
Aurobindo Pharma has submitted copies of newspaper advertisements containing its Q4 and FY25 financial results, published in Business Standard and Nava Telangana on May 28, 2025, as required under SEBI Listing Regulations. On a consolidated basis, FY25 revenue from operations stood at ₹317,237 million with a net profit after tax of ₹37,872 million, translating to an EPS of ₹59.81. For Q4 FY25 alone, consolidated revenue came in at ₹83,821 million versus ₹75,802 million in Q4 FY24, while net profit after tax jumped to ₹10,425 million from ₹7,968 million in the year-ago quarter. On a standalone basis, FY25 revenue was ₹109,333 million and PAT was ₹17,488 million (EPS ₹29.97), with Q4 FY25 standalone PAT at ₹4,082 million.
The strong YoY profit growth (~31% in Q4 consolidated PAT) signals healthy operational momentum, though this filing is a routine compliance disclosure and the detailed results were already filed with exchanges earlier. Investors should look at the underlying detailed filing for segment-wise and margin commentary.